Peptide Profile
NAD+
Peptide Classification:
CLINICAL DEVELOPMENT STAGE:
Not Applicable
Nicotinamide adenine dinucleotide (NAD+) is an oxidized cellular coenzyme that plays a central role in energy metabolism and redox reactions by accepting and transferring electrons. It also serves as a substrate for multiple NAD+-dependent enzymes involved in cellular signaling, DNA repair, and metabolic regulation.
Compound Overview
Molecular Formula
C₂₁H₂₇N₇O₁₄P₂
Molecular Weight
663.4 g/mol
CAS Number
53-84-9
Classification
Peptide Classification:
Regulatory Status
Investigational for exogenous therapeutic use; not FDA approved as a drug for the uses commonly marketed with NAD+
Targets / Receptors
Broad enzymatic cofactor rather than a single receptor target; participates in NAD+-dependent redox reactions and serves as a substrate for NAD+-consuming enzymes such as sirtuins and PARPs.
Research Focus
Cellular energy metabolism; redox biology; mitochondrial function; NAD+-dependent signaling; DNA repair; aging biology; metabolic regulation; and the pharmacokinetics and tolerability of exogenous NAD+ administration.
Mechanism of Action
NAD+ functions primarily as an electron-accepting coenzyme in oxidation-reduction reactions. During metabolism, NAD+ accepts electrons and is reduced to NADH; NADH can then donate those electrons in downstream biochemical reactions, including processes involved in cellular energy production.
NAD+ also serves as a substrate for enzymes including sirtuins and poly(ADP-ribose) polymerases (PARPs), linking cellular NAD+ availability to metabolic signaling and DNA-repair pathways. Because NAD+ participates broadly across cellular metabolism rather than acting through a single receptor, its biological effects are highly context-dependent.
Research Evidence
Human clinical evidence for direct exogenous NAD+ administration remains limited, particularly compared with the much larger literature evaluating NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide.
Direct injectable NAD+ is currently being studied for absorption and tolerability across multiple routes of administration, including intramuscular, subcutaneous, and intravenous administration. These studies are intended to clarify basic pharmacokinetic and tolerability questions that remain incompletely characterized.
Clinical research should distinguish direct NAD+ administration from supplementation with NAD+ precursors. Evidence showing that a precursor raises NAD+ concentrations should not automatically be interpreted as evidence for the safety or efficacy of administering NAD+ itself.
NAD+ is a fundamental endogenous coenzyme, but its role in normal cellular physiology does not by itself establish therapeutic benefit from exogenous administration. Additional controlled human research is needed to characterize dosing, pharmacokinetics, safety, and clinical outcomes.
Safety & Limitations
Clinical safety data for direct NAD+ administration remain limited, and safety depends substantially on formulation, route of administration, sterility, and product quality.
FDA has specifically warned compounders about the use of food-grade NAD+ in sterile injectable preparations, noting that ingredients intended for food use may carry microbial or endotoxin contamination risks and are not suitable for sterile compounding without appropriate processing.
Evidence regarding oral NAD+ precursors should not be assumed to apply to injected or otherwise directly administered NAD+. Controlled clinical data remain limited for many of the therapeutic claims commonly associated with NAD+ administration.
Key References
Direct intravenous NAD+ has been studied in humans, but published clinical data remain limited. A small pilot study examined the NAD+ metabolome during a six-hour intravenous NAD+ infusion. The researchers found that infused NAD+ was rapidly removed from plasma during at least the first two hours, with changes in NAD+-related metabolites and urinary excretion occurring later in the infusion. View study on PubMed.
The pharmacokinetics of directly administered NAD+ are still being characterized. A randomized controlled study registered with ClinicalTrials.gov is evaluating NAD+ administered by intramuscular, subcutaneous, and intravenous-push routes, using NAD+ as an active comparator to injectable nicotinamide riboside. The study reflects continued investigation into the absorption and tolerability of injectable NAD+. View study on ClinicalTrials.gov.
Evidence involving NAD+ precursors should not be treated as evidence for direct NAD+ administration. Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and NAD+ are biologically related but distinct compounds with different pharmacokinetic considerations. Findings from studies of NAD+ precursors therefore cannot automatically establish the safety, pharmacokinetics, or clinical effects of injected NAD+.
FDA has reported adverse events associated with injectable NAD+ products. Reported reactions have included severe chills, shaking, vomiting, and fatigue, with some individuals requiring medical treatment. FDA noted that these reactions were consistent with excessive endotoxin exposure and emphasized the importance of using ingredients suitable for sterile drug compounding. Review the FDA safety communication.
Biological importance does not establish therapeutic efficacy. NAD+ is fundamental to cellular energy metabolism, redox reactions, and NAD+-dependent enzymatic processes, but controlled human evidence supporting many proposed benefits of exogenous NAD+ administration remains limited. Additional research is needed to establish route-specific pharmacokinetics, safety, dosing parameters, and clinical outcomes.
Last scientifically reviewed: 09/08/2026